The Uptick Newswire Stock Day Podcast features Medifocus, Inc. (OTCQB: MDFZF and TSXV: MFS) ("Medifocus" or the "Company"), a biotechnology company with a portfolio of medical technologies that utilize patented Focal Microwave Thermal Technology to treat conditions ranging from Prostate Diseases to Breast Cancer. William Jow, M.D., President, CEO of Medifocus, talked with host Mr. Everett Jolly.
Dr. Jow began the interview by explaining, “I am also a practicing urologist who has always been interested in minimally invasive treatments for the enlarged prostate, or BPH, and prostate cancer. After having practiced medicine for over 30 years, I’m fully aware of the potential side effects of medications and surgeries, therefore I am always looking for the best possible treatment options for my patients; that’s how I initially got involved with Medifocus, first as an end user of Prolieve®, then Medical Director, and now CEO,” explained Dr. Jow.
Dr. Jow went on to say after he saw how his patients improved after being treated with Prolieve®, he is convinced it is one of the best and safest treatment options for most men with symptomatic BPH.
“Recently the FDA has approved our 5-year follow up study which confirms the safety, efficacy, and very positive long-term durable outcome of Prolieve®. The certified and independently conducted FDA Post Market Study clearly demonstrated improvement of voiding symptoms, urinary flow rate and quality of life,” Dr. Jow commented.
Dr. Jow added that it is an important milestone that these findings have been approved by the FDA because now Medifocus can levege the positive clinical findings to promote Prolieve®. Mr. Jolly then asked what makes Prolieve®different from other products on the markets and asked to be walked through the treatment.
“Prolieve® is the only Transurethral Thermodilatation™ (TUTD™) device on the market now,” Dr. Jow explained. He also said it comes with a patented dilating balloon combination that enables it to deliver lower energy thermotherapy and provides immediate symptomatic relief with a safety profile that exceeds any competitors. Dr. Jow also added, “The patient does not feel the discomfort associated with high energy treatments.”
Dr. Jow went on to explain Medifocus is currently exploring the opportunity of using Prolieve® in focal therapy for prostate cancer. He said he hopes they can help a large percentage of those with prostate cancer avoid surgery and radiation and their side effects.
“Right after our first interview with you, about a month ago, we submitted a new patent application for a new innovated Microwave Cluster Tissue Ablation technology to the U.S. patent office adding to our already large portfolio of patents,” said Dr. Jow.
Mr. Jolly then asked about the Company's plans for Breast Cancer treatment. Dr. Jow said they are working with the FDA on APA 1000, and the new patent they submitted will also help with the breast cancer treatment. To date, Phase I and II clinical trials have been completed with positive outcomes; Phase III has been approved by the FDA and awaits funding to start.
“Our innovative approach will likely enhance the efficacy and reduce the systemic side effects of immunotherapy and chemotherapy agents. It’s certainly very exciting,” said Dr. Jow.
Dr. Jow then explained that Medifocus is a small company that has become self-sustainable through its revenue generating Prolieve® operation. He says they have assembled an excellent staff that constantly adds value to the company through research and development.
“I’m confident we can bring the best-in-class, minimally invasive treatment options to our patients through our passion and clinical experience,” said Dr. Jow.
To listen to the entire interview with Dr. Jow, follow this link: https://upticknewswire.com/featured-interview-ceo-dr-william-jow-of-medifocus-inc-otcqb-mdfzf/
About the Prolieve® Thermodilatation™ System
The Prolieve® Thermodilatation™ System offers potential alleviation to the a huge number of men who experience the ill effects of Benign Prostatic Hyperplasia (BPH), a condition that ends up regular as men age. About portion of men, more than 50 have some augmentation of the prostate organ, and this ascents to about 90% among those more than 70. As the prostate amplifies, it chokes the urethra, in this way confining the section of pee. Industrious confinement and further movement of BPH, whenever left untreated, regularly brings about the compounding of lower urinary tract side effects (LUTS). Further confusions of this procedure may result in urinary maintenance, bladder stones and contamination, and additionally traded off bladder and kidney work.
No comments:
Post a Comment